Lipton, Jeffrey H. http://orcid.org/0000-0001-7391-7168
Funding for this research was provided by:
Ascentage Pharma Group Corp Ltd
Article History
Accepted: 12 November 2023
First Online: 5 January 2024
Declarations
:
: Jeffrey H. Lipton reports serving as a consultant for Bristol-Myers Squibb Company (BMS), Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Ltd.; receiving research funding from BMS, Novartis, Pfizer, and Takeda; and receiving honoraria from BMS, Novartis, Incyte Corporation, Pfizer, and Takeda.
: This study and report were supported by Ascentage Pharma Group Corp Ltd (Hong Kong). The sponsor played a role in the conception and design of the review; manuscript research, development, and preparation; and the decision to publish the findings. Jeffrey H. Lipton was not compensated for his role in authoring this publication, had free and unfettered access to all data (published references), and was responsible for all decisions concerning intellectual content.
: Not applicable.
: Not applicable.
: Not applicable.
: All data generated or analyzed during this study are included in this published article.
: Not applicable.
: JHL was responsible for the conception, planning, and writing of this review and approved the final draft.